A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MNTX / methylnaltrexone

[Related PubMed/MEDLINE]
Total Number of Papers: 50
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MNTX  (>> Co-occurring Abbreviation)
Long Form:   methylnaltrexone
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Design and feasibility of a double-blind, randomized trial of peri-operative methylnaltrexone for postoperative ileus prevention after adult spinal arthrodesis. POI
2021 First-Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis. AEs, OIC, RFL
2021 Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. HNSCC, MOR
2021 Morphine promotes themalignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway. CCK-8, MOR, mTOR, PI3K, PP1, Src
2021 The Efficacy and Safety of Methylnaltrexone for the Treatment of Postoperative Ileus. LOS, POI
2020 Antagonism of peripheral opioid receptors by methylnaltrexone does not prevent morphine tolerance in rats. NTX
2020 Methylnaltrexone and Naloxone for Opioid-induced Constipation in the Critical Care Setting. GI, OIC
2020 Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice. NTX
2018 Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids. NTX
10  2018 Involvement of central opioid receptors in protective effects of methadone on experimental colitis in rats. i.c.v, IL-1beta, NTX, s.c, TNF-alpha
11  2017 Effect of methylnaltrexone and naloxone on esophageal motor function in man. ENS, EO, HRIM, NA, UES
12  2017 Methylnaltrexone Versus Naloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit. BM, OIC
13  2017 Pharmacokinetic study of methylnaltrexone after single and multiple subcutaneous administrations in healthy Chinese subjects. SC
14  2016 Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomes. CIs, OIC, RRs
15  2016 Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. CI, HR, MOR, OIC, OS
16  2015 Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects. CTT, MNTX-IR, OCT, WGT
17  2015 Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. OIC, OLE, RCT, RFBM
18  2015 Opioid-induced constipation in chronic noncancer pain. ClC-2, OIC, PAMORA
19  2015 Peripheral opioid antagonist enhances the effect of anti-tumor drug by blocking a cell growth-suppressive pathway in vivo. DOC, GCs, OGF
20  2015 The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants. ---
21  2013 Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. MNTX-PC
22  2013 Effects of methylnaltrexone on guinea pig gastrointestinal motility. GI, LMMP, muOR
23  2013 Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies. CNCP, GERD, NBS, OBD, OIBD
24  2012 (3R,4R,4aS,7aR,12bS)-3-Cyclo-propyl-methyl-4a,9-dihy-droxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octa-hydro-1H-4,12-methano-benzofuro[3,2-e]isoquinolin-3-ium bromide. ---
25  2012 Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. GI
26  2011 Quantitative determination of methylnaltrexone in human serum using liquid chromatography-tandem mass spectrometry. ---
27  2010 In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. AKR
28  2010 Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. ---
29  2010 Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. EC, MOR, mTOR
30  2010 The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. s.c
31  2010 The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. LLC, MOR, NSCLC
32  2010 The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. OIC
33  2009 Use of FDA approved methamphetamine to allow adjunctive use of methylnaltrexone to mediate core anti-growth factor signaling effects in glioblastoma. BBB, EGF, MA, VEGF
34  2008 Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. 5-FU, EC, VEGF
35  2007 A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. ---
36  2007 Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. EC, MOPr
37  2007 The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. GI, POI
38  2006 Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. M3G, M6G, MS, siRNA
39  2006 Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine. ---
40  2005 In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure. ---
41  2003 Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. HIV
42  2002 A review of the potential role of methylnaltrexone in opioid bowel dysfunction. CNS, GI, OBD
43  2002 Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study. HPLC, LOD, LOQ, SPE
44  2002 Methylnaltrexone Progenics. ---
45  2001 Pharmacokinetic profile of epidurally administered methylnaltrexone, a novel peripheral opioid antagonist in a rabbit model. ---
46  1999 Opioid antagonist modulation of ischaemia-induced ventricular arrhythmias: a peripheral mechanism. AS, NTX, VF
47  1999 Peripheral opioid receptors may mediate a portion of the aversive and depressant effect of EtOH: CPP and locomotor activity. CPP, EtOH, TIQs
48  1998 Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine. ---
49  1994 Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. VE80
50  1993 Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs. ---